Descripción de negocio
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. It develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. They invented proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.
Consejo de gestión & Consejo de supervisión
| CEO |
| Dan Hicklin |
| Consejo de gestión |
| Tim Trost, Randi Isaacs, Chulani Karunatilake, Ellen Lubman, Cynthia Seidel-Dugan |
| Consejo de supervisión |
| Luke Evnin, Michael Atkins, Meeta Chatterjee, Derek DiRocco, Dan Hicklin, Alon Lazarus, Briggs W. Morrison, Mike Sherman |
Datos de la empresa
| Nombre: |
Werewolf Therapeutics Inc |
| Dirección: |
200 Talcott Avenue, 2nd Floor,Watertown, MA 02472 |
| Teléfono: |
+1 617-952-0555 |
| Fax: |
- |
| E-mail: |
info@werewolftx.com
|
| Internet: |
https://werewolftx.com/ |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
- |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
29/04/2021 |
Relación con inversores
| Nombre: |
Josh Rappaport |
| IR teléfono: |
+1 212-362-1200 |
| IR-fax: |
- |
| IR e-mail: |
IR@werewolftx.com
|
